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Abstract
Background: Randomised controlled trials demonstrate a 60% reduction in type 2 diabetes incidence through lifestyle
modification programmes. The aim of this study is to determine whether such programmes are feasible in primary health
care.
Methods: An intervention study including 237 individuals 40–75 years of age with moderate or high risk of developing
type 2 diabetes. A structured group programme with six 90 minute sessions delivered during an eight month period by
trained nurses in Australian primary health care in 2004–2006. Main outcome measures taken at baseline, three, and 12
months included weight, height, waist circumference, fasting plasma glucose and lipids, plasma glucose two hours after
oral glucose challenge, blood pressure, measures of psychological distress and general health outcomes. To test
differences between baseline and follow-up, paired t-tests and Wilcoxon rank sum tests were performed.
Results: At twelve months participants' mean weight reduced by 2.52 kg (95% confidence interval 1.85 to 3.19) and waist
circumference by 4.17 cm (3.48 to 4.87). Mean fasting glucose reduced by 0.14 mmol/l (0.07 to 0.20), plasma glucose two
hours after oral glucose challenge by 0.58 mmol/l (0.36 to 0.79), total cholesterol by 0.29 mmol/l (0.18 to 0.40), low
density lipoprotein cholesterol by 0.25 mmol/l (0.16 to 0.34), triglycerides by 0.15 mmol/l (0.05 to 0.24) and diastolic
blood pressure by 2.14 mmHg (0.94 to 3.33). Significant improvements were also found in most psychological measures.
Conclusion: This study provides evidence that a type 2 diabetes prevention programme using lifestyle intervention is
feasible in primary health care settings, with reductions in risk factors approaching those observed in clinical trials.
Trial Number: Current Controlled Trials ISRCTN38031372
Published: 19 September 2007
BMC Public Health 2007, 7:249 doi:10.1186/1471-2458-7-249
Received: 9 February 2007
Accepted: 19 September 2007
This article is available from: http://www.biomedcentral.com/1471-2458/7/249
© 2007 Laatikainen et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Public Health 2007, 7:249 http://www.biomedcentral.com/1471-2458/7/249
Page 2 of 7
(page number not for citation purposes)
Background
It is widely recognised that the incidence of type 2 diabe-
tes is high and increasing both in Australia [1] and
throughout the world [2]. Type 2 diabetes is a chronic and
costly disease associated with premature mortality and
high rates of health service utilisation linked with its com-
plications: cardiovascular disease, retinopathy, renal fail-
ure and neuropathy [3].
The risk factors associated with type 2 diabetes onset are
to a large degree preventable. Lifestyle modification, par-
ticularly weight loss and physical activity, can significantly
reduce the risk of type 2 diabetes [4-6]. Diabetes preven-
tion trials using lifestyle modification have been proven
effective in reducing the risk of developing type 2 diabetes
[4-6], and have shown to be even more effective than
pharmacological interventions [6-9]. The Finnish Diabe-
tes Prevention Study [4] investigated the role of lifestyle
interventions in the progression of type 2 diabetes among
individuals with impaired glucose tolerance. Results dem-
onstrated that the incidence of type 2 diabetes decreased
by 58% in the intervention group compared with the con-
trol group, a finding which was directly associated with
lifestyle modification. Two other studies have demon-
strated similar results [5,6]. Randomised controlled trials
with one-to-one counselling and trials using drugs are
expensive. The lifestyle interventions have all lasted sev-
eral years [6,10] and for example in the DPS, the median
number of counselling sessions during a 3-year interven-
tion was 20 [4]. The cost per patient per year in the
DREAM trial [7] where rosiglitazone and ramipril treat-
ments were used was approximately USD 4700. To deter-
mine whether the results obtained in clinical trials could
be replicated in "real world" primary health care settings
with limited resources and existing personnel, the GOAL
intervention study [11], a lifestyle implementation trial
using a structured group programme, was designed in Fin-
land. Whilst the implementation of lifestyle modification
interventions in routine health care pose a great challenge
[12], the results of this programme have demonstrated
that group lifestyle counselling can be effective and feasi-
ble in 'real world' settings for individuals with an elevated
risk of type 2 diabetes [13].
Given that the efficacy of lifestyle modification treatments
have been well established by earlier diabetes prevention
trials [4,6], the need for an additional randomised con-
trolled trial study design in the current programme was
unnecessary. Further, it was considered unethical not to
offer this effective treatment to all individuals in the pro-
gramme. More appropriately, as the evidence supporting
the intervention is so strong, the purpose was to examine
the implementation of the intervention into routine clin-
ical practice [13,14].
The aim of this study was to evaluate the feasibility of the
structured group programme for lifestyle modification in
Australian primary care settings. The results of the first
three months of intervention have been published earlier
[15].
Methods
Design
This study was developed and evaluated as an implemen-
tation trial in a practical setting in order to establish
whether it is possible to achieve findings comparable to
the Diabetes Prevention Study [4]. A longitudinal pre test
and post test study design was used for examining changes
in clinical outcome measures [13].
Recruitment
This study was carried out in the Greater Green Triangle of
Southwest Victoria and Southeast South Australia in
2004–2006 using General Practices in Hamilton, Hor-
sham and Mount Gambier.
Participants were patients presenting at local General
Practices and were screened opportunistically by study
nurses in reception and waiting areas. The Diabetes Risk
Score tool [16], developed from population based epide-
miological studies, was used to identify patients at high
risk of developing type 2 diabetes. A score of 12 or more
was used as a recruitment criterion. More than 1,500 peo-
ple were approached, and of those approximately two
thirds were willing to be screened. Individuals with can-
cer, recent myocardial infarction or stroke, cognitive
impairment, substance abuse, pregnancy or a previous
type 2 diabetes diagnoses were excluded from the study.
Of the 523 subjects whose score was ≥12, 343 subjects
(65.6%) were willing to participate in the study.
Those (n = 32) who were diagnosed with type 2 diabetes
based on their baseline fasting plasma glucose value (≥7.0
mmol/l) and/or two-hour oral glucose tolerance test
(>11.0 mmol/l) were excluded from the analyses [17]. In
total, 311 participants (88 males and 223 females) aged
40–75 years were eligible to participate. The mean risk
score for eligible participants was 15.7 equating to a one
in three chance of developing type 2 diabetes during the
following 10 years [16].
Intervention
The intervention model used in the study was based on
the diabetes prevention project in the Finnish GOAL study
described in detail elsewhere [11]. Briefly, the interven-
tion consists of six structured 90 minute group sessions
over eight months using the Health Action Process
Approach.BMC Public Health 2007, 7:249 http://www.biomedcentral.com/1471-2458/7/249
Page 3 of 7
(page number not for citation purposes)
The first five sessions occurred within the first three
months, with two week intervals between sessions. The
last session took place at eight months. The sessions were
facilitated by specially trained study nurses, dietitians and
physiotherapists. A goal setting approach was used to
motivate individuals to progress from intention to actual
behaviour change. Regular self-assessment was used to
empower participants to take responsibility for their own
decisions and to make informed choices. Session content
for diet and physical activity was based on Dietary Guide-
lines for Australian Adults [18] and National Physical
Activity Guidelines for Adults [19]. Social support was
enhanced by the group setting and by encouraging partic-
ipants to seek support from their own social networks.
Intervention targets followed the lifestyle targets in the
Finnish Diabetes Prevention Study [4] aiming to reduce
weight, total and saturated fat intake and increase fibre
intake and physical activity.
Measurements
Clinical measurements included height, weight, waist, hip
and blood pressure measurements, all of which were
taken by study nurses before the intervention, at three
months, and at one year. Height, weight, waist, hip and
blood pressure were measured following the European
Health Risk Monitoring protocol [20]. Blood pressure was
measured using a mercury sphygmomanometer.
Fasting venous samples were drawn at the baseline, at
three months, and at one year. All participants were
required to fast overnight prior to each clinical test for a
minimum of eight hours. A quality control was performed
before each clinical test by asking participants the dura-
tion of their fasting period. Fasting hours ranged between
9–17 hours. Oral glucose tolerance tests using 75 g glu-
cose was performed at baseline and twelve months. The
ranges used for impaired glucose values were fasting glu-
cose 6.1 to 6.9 mmol/l (impaired fasting glucose, IFG) or
plasma glucose concentration 7.8 to 11.0 mmol/l two
hours after the oral administration of 75 g of glucose
(impaired glucose tolerance, IGT) [17,20]. Frozen plasma
samples were transferred to Flinders Medical Centre clini-
cal trials laboratory. A Hitachi 917 clinical chemical ana-
lyser (Roche Diagnostic, Australia) was used to measure
plasma glucose, total cholesterol, triglycerides and high
density lipoprotein (HDL) cholesterol by standard enzy-
matic methods. A direct HDL-cholesterol method was
used. Low density lipoprotein (LDL) cholesterol was cal-
culated using the Friedewald equation unless triglycerides
were greater than 4.5 mmol/l. The Flinders Medical Cen-
tre Clinical Trials laboratory participates in Centers for
Disease Control and Prevention Lipid Standardisation
Program.
At baseline and 12 months, participants were assessed
using the Kessler 10 Psychological Distress Scale (K-10)
[21] and Hospital Anxiety and Depression Scale (HADS)
[22]. General health was assessed using Short Form 36
(SF-36v2) [23].
Statistical analyses
Sample size calculations to detect a 5% reduction in main
outcome variables such as weight, serum cholesterol,
blood glucose etc. with 80% power at the 5% significance
level were carried out.
Statistical analyses were performed using SPSS Version 14.
To test differences between baseline and follow-up, paired
t-tests were used. For psychosocial data, Wilcoxon rank
sum tests were performed. Effect sizes were calculated for
changes in psychological and general health measures by
dividing the change in means by the standard deviation of
the baseline mean [24].
Ethics
Participants gave written consent to participate. The study
was approved by the Flinders University Clinical Research
Ethics Committee (reference number 105/034).
Results
Baseline characteristics of completers and non-completers
Out of 311 who started in the intervention, 237 (65 males
and 172 females) attended both the baseline and 12
month clinical tests and at least one group session. This
was the definition of completion. Forty-three percent of
completers participated in all six sessions and only 9.7%
in three or less sessions. Reasons for non-completion
were: lack of transport, fuel costs, time constraints, poor
literacy and health conditions.
The baseline characteristics of those who completed the
program were compared with those who did not. Com-
pared with completers, non-completers had significantly
higher waist circumferences, lower levels of education and
higher scores on measures of psychological distress, anxi-
ety and depression (Table 1). In most domains of the SF-
36v2, non-completers reported poorer health.
Clinical outcomes for completers
Between baseline and twelve months, statistically signifi-
cant improvements were observed in participants' mean
clinical indicators except systolic blood pressure (Table
2). The greatest improvement (8.6%) was seen in plasma
glucose after two hours oral glucose challenge. Total cho-
lesterol declined 5.1%, LDL cholesterol 7.3% and triglyc-
erides 7.6%, whilst HDL cholesterol increased 4.4%.
Waist, weight and diastolic blood pressure declined 4.0%,
2.7% and 2.6%, respectively. Seventy-five percent of par-BMC Public Health 2007, 7:249 http://www.biomedcentral.com/1471-2458/7/249
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ticipants experienced some waist reduction and 68%
experienced weight reduction.
Statistically significant improvements to weight, waist,
total and LDL-cholesterol were evident after the first three
months of the intervention and these changes were sus-
tained at 12 months. Although not observed at 3 months,
statistically significant improvements were found in fast-
ing glucose, HDL-cholesterol, triglycerides and diastolic
blood pressure at 12 months.
At baseline, 65.9% of participants had normal glucose val-
ues and 34.1% had impaired glucose values (IFG 9.5%,
IGT 24.6%). At the 12 month clinical test, 78.0% had nor-
mal glucose values and 19.8% had impaired values (IFG
6.5%, IGT 13.4%). Out of 79 participants who had
impaired values at baseline, five (2.2%) developed type 2
diabetes during the intervention and 42 (18.1%) reverted
to normoglycemia.
Psychological and general health outcomes
Between baseline and 12 month clinical tests, improve-
ments in SF-36v2 domains of vitality and general health
were moderate (Table 3). Small but statistically significant
improvements were observed in the domains of bodily
pain, physical functioning and mental health as well as for
measures of psychological distress (Kessler 10, HADS).
Discussion
This study provides convincing evidence that a type 2 dia-
betes prevention programme using lifestyle intervention
is feasible in Australian primary health care with reduc-
tions in risk factors approaching those observed in ran-
domised controlled trials [4-6]. Results from the present
study confirm that significant changes can be obtained in
weight, waist, glucose and lipids, and psychological meas-
ures.
The implementation of this trial in a "real world" setting
has allowed findings to be more generalisable to primary
health care, as they have been performed in a setting in
which future implementation is likely to occur [14]. Using
the DPS sample as a reference population to predict a
reduction in type 2 diabetes risk, by using a single pre-test
and post-test study design [13], it can be estimated that
the 4.0% decline in waist circumference in our study
reduces the risk of type 2 diabetes by 40%. Alternatively,
calculating the risk reduction using weight change the dia-
betes risk could reduce by 23%. Based on cohort studies,
waist circumference is a better predictor for type 2 diabe-
tes [25], making the risk prediction based on waist proba-
bly a more accurate estimate. Additionally, in this study
the components of metabolic syndrome and the risk fac-
tors for cardiovascular disease were improved.
Table 1: Baseline characteristics of completers and non-
completers
Characteristic Completers (n 
= 237) mean 
(SD)
Non-
completers (n 
= 74) mean 
(SD)
P value
Age (yr) 56.7 (8.7) 57.2 (9.5) 0.705
Weight (kg) 91.7 (17.7) 95.3 (19.6) 0.145
Body-mass 
index (kg/m2)
33.5 (5.9) 34.7 (6.9) 0.144
Waist 
circumference 
(cm)
104.9 (13.0) 109.6 (14.9) 0.009
Hip 
circumference 
(cm)
115.7 (12.5) 117.6 (13.9) 0.257
Plasma glucose 
(mmol/l)
Fasting 5.53 (0.54) 5.46 (0.51) 0.298
2 Hr oral 
glucose 
challenge
6.71 (1.68) 6.61 (1.72) 0.644
Serum lipids 
(mmol/l)
Total 
cholesterol
5.67 (1.15) 5.42 (0.98) 0.102
Low-density 
lipoprotein 
cholesterol
3.44 (0.99) 3.25 (0.80) 0.097
High-
density 
lipoprotein 
cholesterol
1.34 (0.37) 1.26 (0.34) 0.082
Triglyceride
s
1.94 (1.05) 2.02 (1.14) 0.569
Blood pressure 
(mm Hg)
Systolic 132.1 (17.1) 135.0 (18.8) 0.216
Diastolic 81.0 (9.9) 82.6 (11.7) 0.265
HADS anxiety 3.6 (3.3) 5.4 (4.0) <0.0005
HADS 
depression
2.8 (2.9) 4.1 (3.9) 0.014
Kessler 10 
(psychological 
distress)
15.3 (5.4) 19.0 (8.0) <0.0005
SF-36 v2
Physical 
functioning
78.3 (18.6) 66.3 (26.3) 0.001
Role limitation 
physical
78.6 (22.4) 67.3 (29.6) 0.008
Bodily pain 63.0 (23.9) 57.8 (27.5) 0.107
General health 
perception
65.9 (18.6) 61.0 (18.9) 0.034
Vitality 56.4 (19.2) 50.1 (23.8) 0.023
Social 
functioning
83.2 (20.3) 75.2 (27.3) 0.055
Role limitation 
emotional
85.4 (21.0) 76.9 (27.3) 0.026
Mental health 75.7 (17.0) 66.5 (20.5) <0.0005
Years of 
education
12.1 (3.4) 10.7 (3.1) 0.002BMC Public Health 2007, 7:249 http://www.biomedcentral.com/1471-2458/7/249
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Compared with drug treatment that is largely long term,
successful lifestyle changes have an impact beyond the
intervention period [8,10]. The latest follow up of the
Finnish Diabetes Prevention Study [10] shows that the
impact of lifestyle modification will last at least several
years after intervention and the reduction in diabetes inci-
dence was still 36% lower in the intervention group com-
pared with the control group after a median three years.
There is no evidence about the long term impact of drug
treatment and it could be assumed that when drug treat-
ment is ended the treatment effect may disappear [8].
This is the first diabetes prevention study where the clini-
cal significance of psychosocial risk factors were identi-
fied. When investigating the characteristics of completers
and non-completers, it was found that at baseline non-
completers had fewer years of education and greater levels
of psychological distress. Future programmes, should give
more attention to these factors when considering strate-
gies to improve retention rates. In both the present and
previous diabetes prevention studies, more women than
men have attended the programmes [4-6,13]. More
emphasis should therefore be put on identifying the bar-
riers to male attendance. Although this intervention was
feasible and effective for 60% of those who were screened
positively for the risk of type 2 diabetes, there is a need to
develop other approaches for those who may not take part
in group interactive programmes.
Findings from earlier studies suggest that participant
weight loss can be predicted by facilitator motivation and
self-fulfilment [26]. It was also our experience that appro-
priate facilitator training and support are imperative.
Table 3: Mean scores and standard deviations of participant responses to psychological measures and proportion of participants whose 
scores improved between baseline and 12 month intervention
n Baseline mean (SD) Change from baseline to 12 
months mean (95% CI)
Effect size P value
Kessler 10 Psychological distress 226 15.1 (5.2) 14.6 (5.6) +0.10 0.002
HADS Depression 224 2.8 (2.9) 2.5 (3.0) +0.10 0.008
SF-36 v2 Physical Functioning 229 78.5 (18.1) 80.1 (19.9) -0.09 0.012
Role-Physical 230 78.7 (22.3) 78.3 (24.0) +0.02 0.664
Bodily Pain 232 63.0 (23.9) 66.4 (24.7) -0.14 0.019
General Health 229 65.9 (18.6) 71.3 (17.7) -0.29 <0.0005
Vitality 230 56.5 (19.2) 61.2 (18.9) -0.25 <0.0005
Social Functioning 232 83.1 (20.4) 82.7 (23.1) +0.02 0.821
Role-Emotional 230 85.3 (21.2) 85.7 (21.4) -0.02 0.726
Mental Health 230 75.9 (16.8) 78.4 (16.1) -0.15 0.025
Table 2: Changes in clinical outcome in baseline, three months and 12 months
n Baseline mean (SD) Change from baseline to 3 
months* mean (95% CI)
Change from baseline to 12 
months mean (95% CI)
Change at 12 
months %
Weight (kg) 237 91.7 (17.7) -2.38 (-2.79,-1.98) -2.52 (-3.19,-1.85) -2.7
Body-mass index (kg/m2) 237 33.5 (5.9) -0.88 (-1.03,-0.74) -0.93 (-1.17,-0.69) -2.8
Waist circumference (cm) 236 104.9 (13.0) -3.16 (-3.72,-2.60) -4.17 (-4.87,-3.48) -4.0
Hip circumference (cm) 236 115.7 (12.5) -1.56 (-2.04,-1.07) -2.65 (-3.26,-2.05) -2.3
Plasma glucose (mmol/l)
Fasting 237 5.53 (0.54) 0.00 (-0.07,0.08) -0.14 (-0.20,-0.07) -2.5
2 Hr oral glucose challenge 232 6.70 (1.69) - -0.58 (-0.79,-0.36) -8.6
Serum lipids (mmol/l)
Total cholesterol 237 5.67 (1.15) -0.21 (-0.32,-0.09) -0.29 (-0.40,-0.18) -5.1
Low-density lipoprotein 
cholesterol
229 3.44 (0.99) -0.16 (-0.25,-0.07) -0.25 (-0.34,-0.16) -7.3
High-density lipoprotein 
cholesterol
237 1.34 (0.37) 0.01 (-0.02,0.03) 0.06 (0.03,0.09) +4.4
Triglycerides 237 1.90 (1.00) -0.10 (-0.20,0.01) -0.15 (-0.24,-0.05) -7.6
Blood pressure (mmHg)
Systolic 236 132.1 (17.1) -1.67 (-3.3,-0.04) -1.01 (-2.60,0.58) -0.8
Diastolic 236 81.0 (9.9) -0.99 (-2.18,0.20) -2.14 (-3.33,-0.94) -2.6
* At the 3 month clinical test, n value varied between 216 and 221.BMC Public Health 2007, 7:249 http://www.biomedcentral.com/1471-2458/7/249
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Conclusion
This study provides evidence that a type 2 diabetes preven-
tion programme using lifestyle intervention is feasible in
primary health care settings, with reductions in risk factors
approaching those observed in clinical trials.
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